Remus Pharmaceuticals Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Remus Pharmaceuticals Ltd is ₹ 705.75 as of 05 May 15:30 . The P/E Ratio of Remus Pharmaceuticals Ltd is 49.4 as of March 2024 .The P/E Ratio of Vaishali Pharma Ltd is 0 as of March 2024 . The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024 .The Market Cap of Vaishali Pharma Ltd is ₹ 0 crore as of March 2024 . The Revenue of Remus Pharmaceuticals Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of Remus Pharmaceuticals Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of Remus Pharmaceuticals Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Remus Pharmaceuticals Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Remus Pharmaceuticals Ltd or Vaishali Pharma Ltd?

Market cap of Remus Pharmaceuticals Ltd is 831 Cr while Market cap of Vaishali Pharma Ltd is 100 Cr

What are the key factors driving the stock performance of Remus Pharmaceuticals Ltd and Vaishali Pharma Ltd?

The stock performance of Remus Pharmaceuticals Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Remus Pharmaceuticals Ltd and Vaishali Pharma Ltd?

As of May 5, 2026, the Remus Pharmaceuticals Ltd stock price is INR ₹705.75. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.73.

How do dividend payouts of Remus Pharmaceuticals Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Remus Pharmaceuticals Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.